Skip to main content
Erschienen in:

22.08.2023 | Nephrology - Review

Cardiorenal syndrome and iron supplementation—more benefits than risks: a narrative review

verfasst von: Georgia Doumani, Georgios Spanos, Panagiotis Theofilis, Aikaterini Vordoni, Rigas G. Kalaitzidis

Erschienen in: International Urology and Nephrology | Ausgabe 2/2024

Einloggen, um Zugang zu erhalten

Abstract

Intravenous iron administration has emerged as a crucial intervention for managing patients with cardiorenal syndrome (CRS) and iron deficiency, with or without the presence of anemia. Multiple studies have demonstrated the benefits of intravenous iron supplementation in improving anemia, symptoms, and functional capacity in patients with HF and iron deficiency. Furthermore, iron supplementation has been associated with a reduction in hospitalizations for HF exacerbation and the improvement of patients’ quality of life and clinical outcomes. In addition to its effects on HF management, emerging evidence suggests a potential positive impact on kidney function in patients with CRS. Studies have shown an increase in estimated glomerular filtration rate and improvements in renal function markers in patients receiving intravenous iron therapy, highlighting the potential of this intervention in patients with CRS. This paper reviews the existing literature on the impact of intravenous iron therapy in these patient populations and explores its effects on various clinical outcomes. Future research endeavors are eagerly awaited to further improve our understanding of its clinical implications and optimize patient outcomes.
Literatur
1.
Zurück zum Zitat Ronco C, McCullough P, Anker SD, Anand I, Aspromonte N, Bagshaw SM, Bellomo R, Berl T, Bobek I, Cruz DN, Daliento L, Davenport A, Haapio M, Hillege H, House AA, Katz N, Maisel A, Mankad S, Zanco P, Mebazaa A, Palazzuoli A, Ronco F, Shaw A, Sheinfeld G, Soni S, Vescovo G, Zamperetti N, Ponikowski P, Acute Dialysis Quality Initiative (ADQI) consensus group (2010) Cardio-renal syndromes: report from the consensus conference of the acute dialysis quality initiative. Eur Heart J 31(6):703–711. https://doi.org/10.1093/eurheartj/ehp507CrossRefPubMed Ronco C, McCullough P, Anker SD, Anand I, Aspromonte N, Bagshaw SM, Bellomo R, Berl T, Bobek I, Cruz DN, Daliento L, Davenport A, Haapio M, Hillege H, House AA, Katz N, Maisel A, Mankad S, Zanco P, Mebazaa A, Palazzuoli A, Ronco F, Shaw A, Sheinfeld G, Soni S, Vescovo G, Zamperetti N, Ponikowski P, Acute Dialysis Quality Initiative (ADQI) consensus group (2010) Cardio-renal syndromes: report from the consensus conference of the acute dialysis quality initiative. Eur Heart J 31(6):703–711. https://​doi.​org/​10.​1093/​eurheartj/​ehp507CrossRefPubMed
10.
Zurück zum Zitat Opasich C, Cazzola M, Scelsi L, De Feo S, Bosimini E, Lagioia R, Febo O, Ferrari R, Fucili A, Moratti R, Tramarin R, Tavazzi L (2005) Blunted erythropoietin production and defective iron supply for erythropoiesis as major causes of anaemia in patients with chronic heart failure. Eur Heart J 26(21):2232–2237. https://doi.org/10.1093/eurheartj/ehi388CrossRefPubMed Opasich C, Cazzola M, Scelsi L, De Feo S, Bosimini E, Lagioia R, Febo O, Ferrari R, Fucili A, Moratti R, Tramarin R, Tavazzi L (2005) Blunted erythropoietin production and defective iron supply for erythropoiesis as major causes of anaemia in patients with chronic heart failure. Eur Heart J 26(21):2232–2237. https://​doi.​org/​10.​1093/​eurheartj/​ehi388CrossRefPubMed
13.
Zurück zum Zitat Klip IT, Jankowska EA, Enjuanes C, Voors AA, Banasiak W, Bruguera J, Rozentryt P, Polonski L, van Veldhuisen DJ, Ponikowski P, Comin-Colet J, van der Meer P (2014) The additive burden of iron deficiency in the cardiorenal–anaemia axis: scope of a problem and its consequences. Eur J Heart Fail 16(6):655–662. https://doi.org/10.1002/ejhf.84CrossRefPubMed Klip IT, Jankowska EA, Enjuanes C, Voors AA, Banasiak W, Bruguera J, Rozentryt P, Polonski L, van Veldhuisen DJ, Ponikowski P, Comin-Colet J, van der Meer P (2014) The additive burden of iron deficiency in the cardiorenal–anaemia axis: scope of a problem and its consequences. Eur J Heart Fail 16(6):655–662. https://​doi.​org/​10.​1002/​ejhf.​84CrossRefPubMed
14.
Zurück zum Zitat Voors AA, Anker SD, Cleland JG, Dickstein K, Filippatos G, van der Harst P, Hillege HL, Lang CC, Ter Maaten JM, Ng L, Ponikowski P, Samani NJ, van Veldhuisen DJ, Zannad F, Zwinderman AH, Metra M (2016) A systems BIOlogy Study to TAilored Treatment in Chronic Heart Failure: rationale, design, and baseline characteristics of BIOSTAT-CHF. Eur J Heart Fail 18(6):716–726. https://doi.org/10.1002/ejhf.531CrossRefPubMed Voors AA, Anker SD, Cleland JG, Dickstein K, Filippatos G, van der Harst P, Hillege HL, Lang CC, Ter Maaten JM, Ng L, Ponikowski P, Samani NJ, van Veldhuisen DJ, Zannad F, Zwinderman AH, Metra M (2016) A systems BIOlogy Study to TAilored Treatment in Chronic Heart Failure: rationale, design, and baseline characteristics of BIOSTAT-CHF. Eur J Heart Fail 18(6):716–726. https://​doi.​org/​10.​1002/​ejhf.​531CrossRefPubMed
15.
Zurück zum Zitat Alnuwaysir RIS, Grote Beverborg N, Hoes MF, Markousis-Mavrogenis G, Gomez KA, van der Wal HH, Cleland JGF, Dickstein K, Lang CC, Ng LL, Ponikowski P, Anker SD, van Veldhuisen DJ, Voors AA, van der Meer P (2022) Additional burden of iron deficiency in heart failure patients beyond the cardio-renal anaemia syndrome: findings from the BIOSTAT-CHF study. Eur J Heart Fail 24(1):192–204. https://doi.org/10.1002/ejhf.2393CrossRefPubMed Alnuwaysir RIS, Grote Beverborg N, Hoes MF, Markousis-Mavrogenis G, Gomez KA, van der Wal HH, Cleland JGF, Dickstein K, Lang CC, Ng LL, Ponikowski P, Anker SD, van Veldhuisen DJ, Voors AA, van der Meer P (2022) Additional burden of iron deficiency in heart failure patients beyond the cardio-renal anaemia syndrome: findings from the BIOSTAT-CHF study. Eur J Heart Fail 24(1):192–204. https://​doi.​org/​10.​1002/​ejhf.​2393CrossRefPubMed
18.
Zurück zum Zitat Macdougall IC, Bock AH, Carrera F, Eckardt KU, Gaillard C, Van Wyck D, Roubert B, Nolen JG, Roger SD, Investigators F-CS (2014) FIND-CKD: a randomized trial of intravenous ferric carboxymaltose versus oral iron in patients with chronic kidney disease and iron deficiency anaemia. Nephrol Dial Transplant 29(11):2075–2084. https://doi.org/10.1093/ndt/gfu201CrossRefPubMedPubMedCentral Macdougall IC, Bock AH, Carrera F, Eckardt KU, Gaillard C, Van Wyck D, Roubert B, Nolen JG, Roger SD, Investigators F-CS (2014) FIND-CKD: a randomized trial of intravenous ferric carboxymaltose versus oral iron in patients with chronic kidney disease and iron deficiency anaemia. Nephrol Dial Transplant 29(11):2075–2084. https://​doi.​org/​10.​1093/​ndt/​gfu201CrossRefPubMedPubMedCentral
20.
Zurück zum Zitat Lewis GD, Malhotra R, Hernandez AF, McNulty SE, Smith A, Felker GM, Tang WHW, LaRue SJ, Redfield MM, Semigran MJ, Givertz MM, Van Buren P, Whellan D, Anstrom KJ, Shah MR, Desvigne-Nickens P, Butler J, Braunwald E, Network NHFCR (2017) Effect of oral iron repletion on exercise capacity in patients with heart failure with reduced ejection fraction and iron deficiency: the IRONOUT HF randomized clinical trial. JAMA 317(19):1958–1966. https://doi.org/10.1001/jama.2017.5427CrossRefPubMedPubMedCentral Lewis GD, Malhotra R, Hernandez AF, McNulty SE, Smith A, Felker GM, Tang WHW, LaRue SJ, Redfield MM, Semigran MJ, Givertz MM, Van Buren P, Whellan D, Anstrom KJ, Shah MR, Desvigne-Nickens P, Butler J, Braunwald E, Network NHFCR (2017) Effect of oral iron repletion on exercise capacity in patients with heart failure with reduced ejection fraction and iron deficiency: the IRONOUT HF randomized clinical trial. JAMA 317(19):1958–1966. https://​doi.​org/​10.​1001/​jama.​2017.​5427CrossRefPubMedPubMedCentral
21.
Zurück zum Zitat Okonko DO, Grzeslo A, Witkowski T, Mandal AK, Slater RM, Roughton M, Foldes G, Thum T, Majda J, Banasiak W, Missouris CG, Poole-Wilson PA, Anker SD, Ponikowski P (2008) Effect of intravenous iron sucrose on exercise tolerance in anemic and nonanemic patients with symptomatic chronic heart failure and iron deficiency FERRIC-HF: a randomized, controlled, observer-blinded trial. J Am Coll Cardiol 51(2):103–112. https://doi.org/10.1016/j.jacc.2007.09.036CrossRefPubMed Okonko DO, Grzeslo A, Witkowski T, Mandal AK, Slater RM, Roughton M, Foldes G, Thum T, Majda J, Banasiak W, Missouris CG, Poole-Wilson PA, Anker SD, Ponikowski P (2008) Effect of intravenous iron sucrose on exercise tolerance in anemic and nonanemic patients with symptomatic chronic heart failure and iron deficiency FERRIC-HF: a randomized, controlled, observer-blinded trial. J Am Coll Cardiol 51(2):103–112. https://​doi.​org/​10.​1016/​j.​jacc.​2007.​09.​036CrossRefPubMed
22.
Zurück zum Zitat Anker SD, Comin Colet J, Filippatos G, Willenheimer R, Dickstein K, Drexler H, Luscher TF, Bart B, Banasiak W, Niegowska J, Kirwan BA, Mori C, von Eisenhart RB, Pocock SJ, Poole-Wilson PA, Ponikowski P, Investigators F-HT (2009) Ferric carboxymaltose in patients with heart failure and iron deficiency. N Engl J Med 361(25):2436–2448. https://doi.org/10.1056/NEJMoa0908355CrossRefPubMed Anker SD, Comin Colet J, Filippatos G, Willenheimer R, Dickstein K, Drexler H, Luscher TF, Bart B, Banasiak W, Niegowska J, Kirwan BA, Mori C, von Eisenhart RB, Pocock SJ, Poole-Wilson PA, Ponikowski P, Investigators F-HT (2009) Ferric carboxymaltose in patients with heart failure and iron deficiency. N Engl J Med 361(25):2436–2448. https://​doi.​org/​10.​1056/​NEJMoa0908355CrossRefPubMed
23.
Zurück zum Zitat Ponikowski P, van Veldhuisen DJ, Comin-Colet J, Ertl G, Komajda M, Mareev V, McDonagh TA, Parkhomenko A, Tavazzi L, Levesque V, Mori C, Roubert B, Filippatos G, Ruschitzka F, Anker SD (2014) Rationale and design of the CONFIRM-HF study: a double-blind, randomized, placebo-controlled study to assess the effects of intravenous ferric carboxymaltose on functional capacity in patients with chronic heart failure and iron deficiency. ESC Heart Fail 1(1):52–58. https://doi.org/10.1002/ehf2.12006CrossRefPubMed Ponikowski P, van Veldhuisen DJ, Comin-Colet J, Ertl G, Komajda M, Mareev V, McDonagh TA, Parkhomenko A, Tavazzi L, Levesque V, Mori C, Roubert B, Filippatos G, Ruschitzka F, Anker SD (2014) Rationale and design of the CONFIRM-HF study: a double-blind, randomized, placebo-controlled study to assess the effects of intravenous ferric carboxymaltose on functional capacity in patients with chronic heart failure and iron deficiency. ESC Heart Fail 1(1):52–58. https://​doi.​org/​10.​1002/​ehf2.​12006CrossRefPubMed
24.
Zurück zum Zitat Ponikowski P, van Veldhuisen DJ, Comin-Colet J, Ertl G, Komajda M, Mareev V, McDonagh T, Parkhomenko A, Tavazzi L, Levesque V, Mori C, Roubert B, Filippatos G, Ruschitzka F, Anker SD, Investigators C-H (2015) Beneficial effects of long-term intravenous iron therapy with ferric carboxymaltose in patients with symptomatic heart failure and iron deficiencydagger. Eur Heart J 36(11):657–668. https://doi.org/10.1093/eurheartj/ehu385CrossRefPubMed Ponikowski P, van Veldhuisen DJ, Comin-Colet J, Ertl G, Komajda M, Mareev V, McDonagh T, Parkhomenko A, Tavazzi L, Levesque V, Mori C, Roubert B, Filippatos G, Ruschitzka F, Anker SD, Investigators C-H (2015) Beneficial effects of long-term intravenous iron therapy with ferric carboxymaltose in patients with symptomatic heart failure and iron deficiencydagger. Eur Heart J 36(11):657–668. https://​doi.​org/​10.​1093/​eurheartj/​ehu385CrossRefPubMed
25.
Zurück zum Zitat Ponikowski P, Kirwan BA, Anker SD, McDonagh T, Dorobantu M, Drozdz J, Fabien V, Filippatos G, Gohring UM, Keren A, Khintibidze I, Kragten H, Martinez FA, Metra M, Milicic D, Nicolau JC, Ohlsson M, Parkhomenko A, Pascual-Figal DA, Ruschitzka F, Sim D, Skouri H, van der Meer P, Lewis BS, Comin-Colet J, von Haehling S, Cohen-Solal A, Danchin N, Doehner W, Dargie HJ, Motro M, Butler J, Friede T, Jensen KH, Pocock S, Jankowska EA, AFFIRM-AHF Investigators (2020) Ferric carboxymaltose for iron deficiency at discharge after acute heart failure: a multicentre, double-blind, randomised, controlled trial. Lancet 396(10266):1895–1904. https://doi.org/10.1016/S0140-6736(20)32339-4CrossRefPubMed Ponikowski P, Kirwan BA, Anker SD, McDonagh T, Dorobantu M, Drozdz J, Fabien V, Filippatos G, Gohring UM, Keren A, Khintibidze I, Kragten H, Martinez FA, Metra M, Milicic D, Nicolau JC, Ohlsson M, Parkhomenko A, Pascual-Figal DA, Ruschitzka F, Sim D, Skouri H, van der Meer P, Lewis BS, Comin-Colet J, von Haehling S, Cohen-Solal A, Danchin N, Doehner W, Dargie HJ, Motro M, Butler J, Friede T, Jensen KH, Pocock S, Jankowska EA, AFFIRM-AHF Investigators (2020) Ferric carboxymaltose for iron deficiency at discharge after acute heart failure: a multicentre, double-blind, randomised, controlled trial. Lancet 396(10266):1895–1904. https://​doi.​org/​10.​1016/​S0140-6736(20)32339-4CrossRefPubMed
27.
Zurück zum Zitat Kalra PR, Cleland JGF, Petrie MC, Thomson EA, Kalra PA, Squire IB, Ahmed FZ, Al-Mohammad A, Cowburn PJ, Foley PWX, Graham FJ, Japp AG, Lane RE, Lang NN, Ludman AJ, Macdougall IC, Pellicori P, Ray R, Robertson M, Seed A, Ford I, Group IS (2022) Intravenous ferric derisomaltose in patients with heart failure and iron deficiency in the UK (IRONMAN): an investigator-initiated, prospective, randomised, open-label, blinded-endpoint trial. Lancet 400(10369):2199–2209. https://doi.org/10.1016/S0140-6736(22)02083-9 Kalra PR, Cleland JGF, Petrie MC, Thomson EA, Kalra PA, Squire IB, Ahmed FZ, Al-Mohammad A, Cowburn PJ, Foley PWX, Graham FJ, Japp AG, Lane RE, Lang NN, Ludman AJ, Macdougall IC, Pellicori P, Ray R, Robertson M, Seed A, Ford I, Group IS (2022) Intravenous ferric derisomaltose in patients with heart failure and iron deficiency in the UK (IRONMAN): an investigator-initiated, prospective, randomised, open-label, blinded-endpoint trial. Lancet 400(10369):2199–2209. https://​doi.​org/​10.​1016/​S0140-6736(22)02083-9
32.
Zurück zum Zitat Ponikowski P, Filippatos G, Colet JC, Willenheimer R, Dickstein K, Luscher T, Gaudesius G, von Eisenhart RB, Mori C, Greenlaw N, Ford I, Macdougall I, Anker SD, Investigators F-HT (2015) The impact of intravenous ferric carboxymaltose on renal function: an analysis of the FAIR-HF study. Eur J Heart Fail 17(3):329–339. https://doi.org/10.1002/ejhf.229CrossRefPubMed Ponikowski P, Filippatos G, Colet JC, Willenheimer R, Dickstein K, Luscher T, Gaudesius G, von Eisenhart RB, Mori C, Greenlaw N, Ford I, Macdougall I, Anker SD, Investigators F-HT (2015) The impact of intravenous ferric carboxymaltose on renal function: an analysis of the FAIR-HF study. Eur J Heart Fail 17(3):329–339. https://​doi.​org/​10.​1002/​ejhf.​229CrossRefPubMed
35.
Zurück zum Zitat Universitätsklinikum H-E, Deutsches Zentrum für H-K-F, Charite University BG (2024) Intravenous iron in patients with systolic heart failure and iron deficiency to improve morbidity & mortality. https://clinicaltrials.gov/show/NCT03036462 Universitätsklinikum H-E, Deutsches Zentrum für H-K-F, Charite University BG (2024) Intravenous iron in patients with systolic heart failure and iron deficiency to improve morbidity & mortality. https://​clinicaltrials.​gov/​show/​NCT03036462
36.
Zurück zum Zitat Mentz RJ, Ambrosy AP, Ezekowitz JA, Lewis GD, Butler J, Wong YW, De Pasquale CG, Troughton RW, O'Meara E, Rockhold FW, Garg J, Samsky MD, Leloudis D, Dugan M, Mundy LM, Hernandez AF, Investigators H-FT (2021) Randomized placebo-controlled trial of ferric carboxymaltose in heart failure with iron deficiency: rationale and design. Circ Heart Fail 14(5):e008100. https://doi.org/10.1161/CIRCHEARTFAILURE.120.008100 Mentz RJ, Ambrosy AP, Ezekowitz JA, Lewis GD, Butler J, Wong YW, De Pasquale CG, Troughton RW, O'Meara E, Rockhold FW, Garg J, Samsky MD, Leloudis D, Dugan M, Mundy LM, Hernandez AF, Investigators H-FT (2021) Randomized placebo-controlled trial of ferric carboxymaltose in heart failure with iron deficiency: rationale and design. Circ Heart Fail 14(5):e008100. https://​doi.​org/​10.​1161/​CIRCHEARTFAILURE​.​120.​008100
37.
Zurück zum Zitat Charite University BG, University of G (2020) Effect of IV iron in patients with heart failure with preserved ejection fraction. https://clinicaltrials.gov/show/NCT03074591 Charite University BG, University of G (2020) Effect of IV iron in patients with heart failure with preserved ejection fraction. https://​clinicaltrials.​gov/​show/​NCT03074591
38.
Zurück zum Zitat Vinke JS, Eisenga MF, Sanders JF, Berger SP, Spikman JM, Abdulahad WH, Bakker SJ, Gaillard C, van Zuilen AD, van der Meer P, de Borst MH (2023) Effect of intravenous ferric carboxymaltose on exercise capacity after kidney transplantation (EFFECT-KTx): rationale and study protocol for a double-blind, randomised, placebo-controlled trial. BMJ Open 13(3):e065423. https://doi.org/10.1136/bmjopen-2022-065423 Vinke JS, Eisenga MF, Sanders JF, Berger SP, Spikman JM, Abdulahad WH, Bakker SJ, Gaillard C, van Zuilen AD, van der Meer P, de Borst MH (2023) Effect of intravenous ferric carboxymaltose on exercise capacity after kidney transplantation (EFFECT-KTx): rationale and study protocol for a double-blind, randomised, placebo-controlled trial. BMJ Open 13(3):e065423. https://​doi.​org/​10.​1136/​bmjopen-2022-065423
39.
Zurück zum Zitat Shah AA, Donovan K, Seeley C, Dickson EA, Palmer AJR, Doree C, Brunskill S, Reid J, Acheson AG, Sugavanam A, Litton E, Stanworth SJ (2021) Risk of infection associated with administration of intravenous iron: a systematic review and meta-analysis. JAMA Netw Open 4(11):e2133935. https://doi.org/10.1001/jamanetworkopen.2021.33935 Shah AA, Donovan K, Seeley C, Dickson EA, Palmer AJR, Doree C, Brunskill S, Reid J, Acheson AG, Sugavanam A, Litton E, Stanworth SJ (2021) Risk of infection associated with administration of intravenous iron: a systematic review and meta-analysis. JAMA Netw Open 4(11):e2133935. https://​doi.​org/​10.​1001/​jamanetworkopen.​2021.​33935
41.
Zurück zum Zitat Macdougall IC, White C, Anker SD, Bhandari S, Farrington K, Kalra PA, McMurray JJV, Murray H, Tomson CRV, Wheeler DC, Winearls CG, Ford I, PIVOTAL Investigators and Committees (2019) Intravenous iron in patients undergoing maintenance hemodialysis. N Engl J Med 380(5):447–458. https://doi.org/10.1056/NEJMoa1810742CrossRefPubMed Macdougall IC, White C, Anker SD, Bhandari S, Farrington K, Kalra PA, McMurray JJV, Murray H, Tomson CRV, Wheeler DC, Winearls CG, Ford I, PIVOTAL Investigators and Committees (2019) Intravenous iron in patients undergoing maintenance hemodialysis. N Engl J Med 380(5):447–458. https://​doi.​org/​10.​1056/​NEJMoa1810742CrossRefPubMed
Metadaten
Titel
Cardiorenal syndrome and iron supplementation—more benefits than risks: a narrative review
verfasst von
Georgia Doumani
Georgios Spanos
Panagiotis Theofilis
Aikaterini Vordoni
Rigas G. Kalaitzidis
Publikationsdatum
22.08.2023
Verlag
Springer Netherlands
Erschienen in
International Urology and Nephrology / Ausgabe 2/2024
Print ISSN: 0301-1623
Elektronische ISSN: 1573-2584
DOI
https://doi.org/10.1007/s11255-023-03741-8

Kompaktes Leitlinien-Wissen Innere Medizin (Link öffnet in neuem Fenster)

Mit medbee Pocketcards schnell und sicher entscheiden.
Leitlinien-Wissen kostenlos und immer griffbereit auf ihrem Desktop, Handy oder Tablet.

Neu im Fachgebiet Innere Medizin

KI erlaubt neue Einsichten in die Krebsprognose

Forschende sind in komplexen Real-World-Daten des Westdeutschen Tumorzentrums auf bisher weniger beachtete Zusammenhänge von bestimmten Risikomarkern mit der Prognose gestoßen. Möglich gemacht hat’s ein Verfahren namens „erklärbare KI“, mit dem sich hunderte Tumor- und Patientenmerkmale gleichzeitig betrachten lassen.

Schwere Menschen brauchen nicht mehr Strom

Die initiale Energiedosis – bezogen auf das Körpergewicht – hat wenig Einfluss auf den Erfolg einer Defibrillation von Erwachsenen mit Herzstillstand. Eine Rückkehr des Spontankreislaufs wird unabhängig von der Energiedichte ähnlich oft erzielt, auch die Überlebensraten sind vergleichbar.

Umfrage: Speicheltest auf Endometriose nutzen nur wenige Gynäkologen

Ein seit 2023 verfügbarer Mikro-RNA-basierter Speicheltest auf Endometriose stößt bei Gynäkologen in Deutschland auf Zurückhaltung. Die meisten meinen: Der Test wird das diagnostische Vorgehen nicht verändern.

Podcast

Magendarminfekte: Dos and Don'ts bei Kleinkindern

Die Leitlinie zur akuten infektiösen Gastroenteritis wurde 2024 umfassend überarbeitet. Cola und Saft zur oralen Hydratation und einige Antidiarrhoika sollten vermieden werden. Von einem standardmäßigen Erregerpanel wird abgeraten. Die Hintergründe zu diesen und weiteren Empfehlungen erläutert Leitlinienkoordinator Prof. Carsten Posovszky.

EKG Essentials: EKG befunden mit System (Link öffnet in neuem Fenster)

In diesem CME-Kurs können Sie Ihr Wissen zur EKG-Befundung anhand von zwölf Video-Tutorials auffrischen und 10 CME-Punkte sammeln.
Praxisnah, relevant und mit vielen Tipps & Tricks vom Profi.

Update Innere Medizin

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.